News releases
40 of 53 items
Presentation of Positive Clinical Data on NPL-2005 22 Jul 2008
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, is pleased to announce the presentation of positive results of its exploratory Phase IIa clinical trial of NPL-2005 in children and adolescents with Fragile X Syndrome.
Appointment of VP Pharmaceutical Development and Manufacturing 15 Jul 2008
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on the development of medicines for the treatment of neurodevelopmental disorders, is pleased to announce the appointment of Dr Marshall Whiteman, a highly experienced pharmacist and chartered engineer, as VP Pharmaceutical Development and Manufacturing.
FDA awards Orphan Drug Designation to NPL-2005 in Fragile X Syndrome 13 May 2008
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, is pleased to announce that the US Food and Drug Administration’s Office of Orphan Product Development has granted Orphan Drug Designation to NPL-2005 for the treatment of Fragile X Syndrome.
FDA grants Fast Track designation to NPL-2008 10 Apr 2008
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, is pleased to announce that the US Food and Drug Administration (FDA) has granted Fast Track designation for Neuropharm’s program to develop NPL-2008 in the treatment of Autism Disorder.
World Autism Awareness Day 2 Apr 2008
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, is proud to support World Autism Awareness Day.
Commencement of Phase II trial of NPL-2009 in Fragile X Syndrome 10 Mar 2008
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, is pleased to announce the commencement of a Phase II trial in Fragile X Syndrome of NPL-2009. NPL-2009 belongs to a class of compounds known as mGluR5 receptor antagonists.
Half-year results for the six months ended 31 December 2007 28 Feb 2008
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company whose lead programme is NPL-2008, a Zydis® formulation of fluoxetine for the treatment of autism, is pleased to announce its half-year results for the six months ended 31 December 2007
Appointment of President US Operations 25 Feb 2008
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on the development of medicines for the treatment of neurodevelopmental disorders, is pleased to announce the US appointment of Bob Prachar, a highly experienced pharmaceutical executive, as President US Operations.
Appointment of VP Business Development 9 Jan 2008
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on the development of medicines for the treatment of neurodevelopmental disorders, is pleased to announce the employment today of Maria Dzaleta as VP Business Development.
AIM Awards Dinner 23 Oct 2007
At the AIM Awards Dinner 2007 on 18th October 2007 Neuropharm Group plc was presented with the AIM Best Technology Award 2007
40 of 53 items